Company Overview

RNA as of 2:27 PM ET on 10/24/14
Price
12.09
Change
+ 0.04
Day High
12.23
Day Low
11.96
20 minute delayed data provided by eSignal
Stock price graph
     

Prosensa is a biopharmaceutical company focused on the discovery, development and commercialization of RNA modulating therapeutics. The company targets genetic disorders with a large unmet medical need, with a primary focus on neuromuscular and neurodegenerative disorders such as Duchenne Muscular Dystrophy (DMD)Myotonic Dystrophy (DM1) and Huntington's Disease (HD).

Prosensa's portfolio of clinical and pre-clinical RNA-based drug candidates is currently focused on the treatment of DMD, with 6 programs currently in development. Prosensa’s lead candidate for the treatment of DMD, drisapersen, has completed Phase III clinical trials. 

Prosensa commenced operations in 2002 and is located in Leiden, The Netherlands. The company works closely together with academia, patient groups and experts worldwide. 

View all »   RSSRecent Releases

Oct 10, 2014
Prosensa begins NDA submission to the FDA for exon-skipping drug drisapersen to treat Duchenne muscular dystrophy

Oct 10, 2014
Prosensa start indiening registratiedossier bij FDA voor Duchenne-medicijn drisapersen